700 related articles for article (PubMed ID: 19797939)
1. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries.
Chan KY; de Vries R; Leijten FP; Pfannkuche HJ; van den Bogaerdt AJ; Danser AH; MaassenVanDenBrink A
Eur J Pharmacol; 2009 Oct; 619(1-3):61-7. PubMed ID: 19619527
[TBL] [Abstract][Full Text] [Related]
3. 5-hydroxytryptamine and platelet aggregation.
De Clerck FF; Herman AG
Fed Proc; 1983 Feb; 42(2):228-32. PubMed ID: 6822293
[TBL] [Abstract][Full Text] [Related]
4. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.
Beattie DT; Higgins DL; Ero MP; Amagasu SM; Vickery RG; Kersey K; Hopkins A; Smith JA
Vascul Pharmacol; 2013 Jan; 58(1-2):150-6. PubMed ID: 23201772
[TBL] [Abstract][Full Text] [Related]
5. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro.
Maayani S; Schwarz T; Craddock-Royal B; Tagliente TM
Platelets; 2001 Sep; 12(6):359-75. PubMed ID: 11672475
[TBL] [Abstract][Full Text] [Related]
6. An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation.
Gurbel PA; Bliden K; Barnett SD; Witt C; Zou H; Tantry U
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):40-50. PubMed ID: 32672062
[TBL] [Abstract][Full Text] [Related]
7. Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae.
Chai W; Chan KY; de Vries R; van den Bogeardt AJ; de Maeyer JH; Schuurkes JA; Villalón CM; Saxena PR; Danser AH; MaassenVanDenBrink A
Life Sci; 2012 Apr; 90(13-14):538-44. PubMed ID: 22326501
[TBL] [Abstract][Full Text] [Related]
8. Whole blood platelet aggregation in humans and animals: a comparative study.
Soloviev MV; Okazaki Y; Harasaki H
J Surg Res; 1999 Apr; 82(2):180-7. PubMed ID: 10090827
[TBL] [Abstract][Full Text] [Related]
9. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
10. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
Oppenheim B; Hefez A; Youdim MB
Prog Biochem Pharmacol; 1980; 16():119-32. PubMed ID: 7443729
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 5-HT4 and 5-HT7 receptor expression and function in the circular muscle of the human colon.
Irving HR; Tan YY; Tochon-Danguy N; Liu H; Chetty N; Desmond PV; Pouton CW; Coupar IM
Life Sci; 2007 Mar; 80(13):1198-205. PubMed ID: 17258778
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
Glusa E; Markwardt F
Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
[TBL] [Abstract][Full Text] [Related]
13. Platelet 5-HT2A-receptor-mediated induction of aggregation is not altered in major depression.
Gómez-Gil E; Gastó C; Díaz-Ricart M; Carretero M; Salamero M; Catalán R; Escolar G
Hum Psychopharmacol; 2002 Dec; 17(8):419-24. PubMed ID: 12457378
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxytryptamine-2A receptor gene (HTR 2 A) candidate polymorphism (T 102 C): Role for human platelet function under pharmacological challenge ex vivo.
Ozdener F; Gülbas Z; Erol K; Ozdemir V
Methods Find Exp Clin Pharmacol; 2005; 27(6):395-400. PubMed ID: 16179957
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human platelet functions by verapamil.
Ikeda Y; Kikuchi M; Toyama K; Watanabe K; Ando Y
Thromb Haemost; 1981 Apr; 45(2):158-61. PubMed ID: 6789494
[TBL] [Abstract][Full Text] [Related]
16. The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations.
Higgins DL; Ero MP; Loeb M; Kersey K; Hopkins A; Beattie DT
Naunyn Schmiedebergs Arch Pharmacol; 2012 Jan; 385(1):103-9. PubMed ID: 21901313
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
18. Tegaserod inhibits the serotonin transporter SERT.
Ismair MG; Kullak-Ublick GA; Blakely RD; Fried M; Vavricka SR
Digestion; 2007; 75(2-3):90-5. PubMed ID: 17510552
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-aminoadamantanes on adenine nucleotide and serotonin storage in blood platelets.
Wesemann W; Muschalek G; Stöltzing H; von Pusch I; Paul N
Eur J Cell Biol; 1981 Dec; 26(1):158-67. PubMed ID: 7327177
[TBL] [Abstract][Full Text] [Related]
20. The in vitro effects of niacin on platelet biomarkers in human volunteers.
Serebruany V; Malinin A; Aradi D; Kuliczkowski W; Norgard NB; Boden WE
Thromb Haemost; 2010 Aug; 104(2):311-7. PubMed ID: 20539903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
